
    
      This two-part study will assess in healthy male and female subjects a solid oral dose
      formulation of CTP-656 vs. KalydecoÂ® and the safety, tolerability and pharmacokinetic
      profiles of escalating CTP-656 solid oral doses following 7 days of dosing. In Part B, three
      doses of CTP-656 ranging from 75 mg up to 300 mg per day will be studied.
    
  